Skip to content

Shop BLIS Probiotics >

  • Solutions

    Probiotic Portfolio

    BLIS K12™

    BLIS M18™

    BLIS Q24™

    Health Areas

    ENT Health

    Immune Health

    Dental Health

    Skin Health

    Finished Goods

    BLIS Q24™ Live Probiotic Serum

    BLIS K12™ Throat Health Lozenge

    BLIS K12™ Immunity Lozenge

    BLIS K12™ Immunity Kids Powder

    BLIS K12™ Fresh Breath Lozenge

    BLIS M18™ Teeth & Gums Lozenge

  • Work With Us

    Private Label

    Ingredients

    R&D and Formulations

  • Research

    Clinical Studies

    Scientific Collaboration

  • Investor Centre

    NZX Announcements

    Annual & Half Year Reports

    Corporate Governance

    Charters & Policies

    FAQs

    Key Dates

    Investor Enquiries

  • Company

    Our Mission

    Our Story

    Facilities

    Partners

  • Knowledge

    Press

    Awards

    White Papers

    Events

CONTACT US
CONTACT US

INVESTOR CENTRE

View Share Price

Main Menu
  • Investor Overview
  • NZX Announcements
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
  • Annual & Half Year Reports
  • Corporate Governance
  • Charters & Policies
  • Frequently Asked Questions
  • Key Dates
  • Investor Enquiries
  • NZX Announcements

Announcements from BLIS Technologies lodged on the NZX

You can view our page on the NZX and our latest NZD share price here.

Click here to go to the Blis information page where you will see the latest news and share price data. For interim and annual results releases and annual reports click here to go to our Annual and Half Year Reports page.

2025 ANNOUNCEMENTS

  • Revenue and Earnings growth 2025
  • 2025-02-21 Third quarter performance update and full year guidance

2024 ANNOUNCEMENTS

  • 2024-11-26 Favourable Result Despite Challenging Economic Backdrop
  • 2024-11-15 Partnership with Chinese Distributor for BLIS Probiotics
  • 2024-10-14 Patent and Commercial Terms in Negotiation
  • 2024-09-24 Trading Halt Release Announcement
  • BLT Shareholder Meeting Results
  • 2024 ASM Script for NZX
  • 2024 ASM Presentation
  • Strong First Quarter Support Profitable Full Year Outlook
  • Notice of Meeting August 2024
  • Proxy Form
  • Virtual Meeting and Online Portal Guide
  • Annual Shareholder Meeting and Director Nominations
  • New Distribution Partner for NZ Pharmacy Channel
  • Revenue growth and a return to profitability
  • Upgraded FY24 earnings guidance
  • Revenue Growth and Profitable Third Quarter

2023 ANNOUNCEMENTS

  • Director Announcement
  • New Chief Executive Appointed
  • Growth of B2B customer base in challenging market conditions
  • Licensing agreement with Emma Lewisham
  • 2023 Annual Shareholder Meeting Results
  • 2023 ASM presentation
  • 2023 ASM Chair and CEO addresses
  • Innovative skincare technology secures new license agreement
  • First Quarter Performance Update
  • Notice of Meeting
  • Proxy Form
  • Virtual Meeting Guide
  • Resignation of Chief Executive Officer
  • Notice of Annual Shareholder Meeting
  • Director Announcement
  • First Quarter Performance Update
  • Revenue growth and a profitable second half year
  • Changes to distribution relationship in North America
  • Upgraded revenue and earnings guidance
  • Third Quarter Performance Update

2022 ANNOUNCEMENTS

  • Director Retirement
  • Strategy reset and revenue growth
  • Senior Leadership Team Changes
  • 2022 Annual Shareholder Meeting Results
  • 2022 ASM Presentation
  • 2022 ASM Chair and CEO Address
  • Refocus Strategy on Core Business
  • Notice of Meeting
  • Proxy Form
  • Virtual Meeting Guide
  • Notice of Annual Shareholder Meeting
  • FY22 Annual Result Release
  • Third Quarter Performance Update
  • Appointment of Marketing and eCommerce Director

2021 ANNOUNCEMENTS

  • Challenging market conditions in US impact half year results
  • 2021 Annual Shareholder Meeting Results
  • ASM Presentation
  • ASM Chair and CEO address
  • Probi Investment and Partnership Briefing - Investor Call Transcription
  • Investor Call Slide Deck – Probi Partnership
  • Investor Call Regarding Announcement of Probi Investment in Blis
  • Notice of Meeting
  • Proxy Form
  • Virtual Meeting Guide
  • 2021 Annual Shareholder Meeting and Director Nominations
  • FY21 Annual Result Release
  • Probiotic Strain Approvals in India
  • Sales Model Revised in Australia
  • Strategic Emphasis on D2C e-Commerce Growth
  • Launch of 3rd Commercial Probiotic Strain to Promote Healthy Skin
  • Business Performance and Year End Guidance Update
  • Tmall Flagship Store Launch

2020 ANNOUNCEMENTS

  • Strong HY21 Performance Despite Challenging Market Conditions
  • Appointment of Exclusive Cross Border eCommerce Service Provider for China
  • Distribution Partner Appointed for Canadian Market
  • 2020 Annual Meeting of Shareholders Results
  • 2020 ASM Chair and CEO address
  • 2020 ASM Presentation
  • Recommendation on Directors Fee Pool
  • Notice of Meeting
  • Proxy Form
  • Virtual Meeting Online Portal Guide
  • Independent Director Fee Review
  • Blis Delivers Sustained profitable growth
  • FY20 Annual Result Release
  • Frank Spiewack Joins the Executive Leadership Team
  • Upgraded FY20 Guidance
  • BLIS Appoints Tony Balfour as a Director
  • Business Update
  • Upgraded Revenue and Earnings
  • Q3 FY20 Performance Update
  • New Product Launch UltraBLIS

2019 ANNOUNCEMENTS

  • NZX Price Enquiry – BLT Response
  • NZX Price Enquiry
  • BLIS ThroatGuard Australian Probiotic Product of the Year
  • All Regions Experiencing Sales Growth
  • BLT Market Update Business Performance
  • BLT 2019 Marketing Awards
  • 2019 Annual Shareholder Meeting Results
  • ASM Presentations and Business Update
  • 2019 Chair & CEO Address
  • 2019 Chair & CEO Presentation
  • BLT Precautionary response completed
  • BLT Chemical Incident at Dunedin Site
  • Notice of Meeting 2019
  • Proxy Form 2019
  • BLT Annual meeting and director nominations
  • M18 Health Canada Approval
  • M18 GRAS No Objection
  • FY19 Guidance 01-04-19
  • Australia Approval BLIS M18
  • Expanded Launch into Australian Market
  • Market Update 3rd Quarter Result FY19

2018 ANNOUNCEMENTS

  • NZX Release - Board Announcement 28 Sept 2018
  • NZX Release 07092018 - iNova
  • NZX Release 20180803 Appointment Barry Richardson
  • 2018 AGM Results
  • ASM2018_Final
  • Blis Technologies Performance Update
  • Notice of Meeting 2018
  • Shareholder Proxy 2018
  • Change of Registered Office and Address
  • Blis Technologies Launch of Products on US Amazon Platform
  • Request Director Nominations
  • Blis Technologies Limited Market Update and Release of Annual Report
  • NZX BLIS Announces New Board Member MAY42018
  • Blis Technologies Achieves Another International Regulatory Milestone
  • Blis Technologies Launch New Flavour Variant of Popular HoneyBlis
  • Callaghan Innovation Grant for Blis Technologies
  • Blis Technologies Update - 22 January 2018

2017 ANNOUNCEMENTS

  • New Distribution Partner for NZ Pharmacy Channel
  • BLIS - Australian Regulatory Approval
  • New Chief Financial Officer Appointment
  • Blis Technologies Ltd- NZX Release - 27 October 2017
  • CFO Resignation-NZX Release
  • Independent Directors and Election of Chair
  • 28072017 Blis AGM Results v2
  • AGM presentation 280717 _Final
  • CEO Presentation 28072017
  • Maspex BLIS K12
  • Director Remuneration Report-NZX release
  • Directors Fees - SESI Report
  • Notice of Meeting-BLT
  • Proxy Form Shareholders - BLT
  • Request for Director Nominations 2017
  • Market Update and Annual Report Release
  • Blis Technologies Limited - Director Resignation
  • Blis Technologies Rreports a Maiden EBITDA Surplus
  • BLT – Independent Director Status
  • Notice under clause 30, Schedule 4 of the Financial Markets Conduct Act 2013
  • SSH Notice - Edinburgh Equity Limited and A P Offen
  • SSH Notice - Minchun Qiu
  • SSH Notice - Wen Wu
  • Updated Guidance
  • New European Study

2016 ANNOUNCEMENTS

  • Amended - Ongoing Disclosure Notice Brian Watson
  • Annual Meeting- Voting Results
  • Blis Technologies Affirms Revenue Expectations
  • Blis Technologies Gets Key ‘Letter of No Objection’ From US Food and Drug Administration for Ingredient BLIS K12
  • Blis Technologies Limited - Half Year Result
  • Blis Technologies Limited - Shareholder Update
  • Blis Technologies Records 123% Increase in Revenues to $5.6m
  • Blis Technologies Wins Two Awards in Deloitte Fast 50
  • Director Independence
  • Independent Research Report
  • Notice of Annual Meeting
  • NOTICE OF CHANGE IN ISSUED SECURITIES – ISSUE OF ORDINARY SHARES
  • Request for Director Nominations
  • Updated Guidance

Solutions

  • Probiotic Portfolio
  • Health Areas
  • Finished Goods

WORK WITH US

  • Ingredients
  • Private Label
  • R&D and Formulations

Other Links

  • Investor Centre
  • Privacy Policy
  • Terms & Conditions
  • Terms of Trade

Connect With Us

  • @blis-technologies-limited
    @blis-technologies-limited
  • Info@blis.co.nz
    Info@blis.co.nz
  • Buy BLIS Probiotics Online:
BlisProbiotics.co.NZ

© 2023 Blis Technologies ·
Website crafted by Drive Digital